Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma

Head and Neck

Volumn 31, Issue 6, 2009, Pages 782-788

  Orlov, Steven ^a   Orlov, David ^a   Shaytzag, Michael ^a   Dowar, Mark ^a   Tabatabaie, Vafa ^a   Dwek, Philip ^a   Yip, Jonathan ^a   Hu, Cindy ^a   Freeman, Jeremy L ^a   Walfish, Paul G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical predictors; DeGroot staging; Patient age; Primary tumor size; pTNM staging; Thyroid carcinoma

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT CANCER; THYROID CANCER; THYROIDECTOMY; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYROGLOBULIN; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 67049156007     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21020     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295: 2164-2167.
3. Grebe SK, Hay ID. Follicular cell-derived thyroid carcinomas. Cancer Treat Res 1997;89:91-140.
4. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990;19:545-576. (Pubitemid 20282656)
5. Park SH, Suh EH, Chi JG. A histopathologic study on 1,095 surgically resected thyroid specimens. Jpn J Clin Oncol 1988;18:297-302.
6. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424. (Pubitemid 20261828)
7. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997; 79:564-573. (Pubitemid 27051783)
8. Greene FL, American Cancer Society, American College of Surgeons, American Joint Committee on Cancer. AJCC cancer staging manual, 6th ed. New York: Springer- Verlag; 2002.
9. Lin JD, Chen ST, Hsueh C, Chao TC. A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid 2007;17:535-541. (Pubitemid 47068116)
10. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89: 3668-3676. (Pubitemid 39089119)
11. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050- 1057; discussion 1057-1058.
12. Chaplin JM, O'Brien CJ, McNeil EB, Haghighi K. Application of prognostic scoring systems in differentiated thyroid carcinoma. Aust N Z J Surg 1999;69:625-628. (Pubitemid 29422132)
13. D'Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 2004;14:453-458. (Pubitemid 38868765)
14. Davis NL, Bugis SP, McGregor GI, Germann E. An evaluation of prognostic scoring systems in patients with follicular thyroid cancer. Am J Surg 1995;170:476-480.
15. Kjellman P, Zedenius J, Lundell G, et al. Predictors of outcome in patients with papillary thyroid carcinoma. Eur J Surg Oncol 2006;32:345-352.
16. Steinmuller T, Klupp J, Rayes N, et al. Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg 2000;166:29-33. (Pubitemid 30062584)
17. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-885.
18. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428. (Pubitemid 24345593)
19. Sugino K, Kure Y, Iwasaki H, et al. Metastases to the regional lymph nodes, lymph node recurrence, and distant metastases in nonadvanced papillary thyroid carcinoma. Surg Today 1995;25:324-328.
20. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142.
21. Cady B, Sedgwick CE, Meissner WA, Bookwalter JR, Romagosa V, Werber J. Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg 1976;184:541-553.
22. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986;61:978-996.
23. Coburn MC, Wanebo HJ. Age correlates with increased frequency of high risk factors in elderly patients with thyroid cancer. Am J Surg 1995;170:471-475.
24. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004;11:571-579. (Pubitemid 39331285)
25. Golger A, Fridman TR, Eski S, Witterick IJ, Freeman JL, Walfish PG. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/ recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest 2003;26:1023-1031. (Pubitemid 38049156)
26. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979;15:1033-1041. (Pubitemid 9254743)
27. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095. (Pubitemid 18010757)
28. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947-953. (Pubitemid 19011971)
29. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 1994; 116:1036-1040; discussion 1040-1041. (Pubitemid 24382163)
30. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012-1021. (Pubitemid 28401936)
31. McDougall IR, Hay ID. ATA Guidelines: do patients with stage I thyroid cancer benefit from (131)I? Thyroid 2007;17:595-596; author reply 596-597.
32. Cheema Y, Repplinger D, Elson D, Chen H. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol 2006;13:1524-1528.
33. Falvo L, Catania A, D'Andrea V, Grilli P, D'Ercole C, De Antoni E. Prognostic factors of insular versus papillary/ follicular thyroid carcinoma. Am Surg 2004;70:461-466.
34. Reddy RM, Grigsby PW, Moley JF, Hall BL. Lymph node metastases in differentiated thyroid cancer under 2 cm. Surgery 2006;140:1050-1054; discussion 1054-1055. (Pubitemid 44937388)
35. Cushing SL, Palme CE, Audet N, Eski S, Walfish PG, Freeman JL. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004;114:2110-2115. (Pubitemid 39602473)
36. Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 2002;128:825-828. (Pubitemid 34755316)
37. Rosen IB, Azadian A, Walfish PG. Adverse aspects of small thyroid cancer and need for treatment. Head Neck 1995;17:373-376.
38. Blahd WH, Drickman MV, Porter CW, Hill VA, Baumgartner WA. Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: concise communication. J Nucl Med 1984;25:673-676. (Pubitemid 14085674)
39. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005;90:5723-5729. (Pubitemid 41415482)
40. Sawka AM, Orlov S, Gelberg J, et al. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma. Head Neck 2008;30:693-700. (Pubitemid 351913843)
41. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 2001;86: 4092-4097.
42. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow- up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-1111. (Pubitemid 36337763)